I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Babesiosis
Definition
Babesiosis is a tick-borne, malaria-like disease caused by intraerythrocytic sporozoan (protozoan) parasites of the genus Babesia. They infect red blood cells and produce a hemolytic illness that can range from subclinical to rapidly fatal.
- Goldman-Cecil Medicine, p. 3450; Robbins Pathology, p. 374
Causative Organisms & Vectors
| Species | Region | Vector |
|---|
| B. microti | Northeastern & upper Midwestern USA, parts of Asia/Europe | Ixodes scapularis (deer tick) |
| B. divergens | Europe | Ixodes ricinus (sheep/castor bean tick) |
| B. duncani (WA-1) | Western USA (California, Washington) | Ixodes spp. |
| B. venatorum / B. crassa | Northeastern China | Ixodes spp. |
Key reservoirs: white-footed mouse (Peromyscus leucopus) and white-tailed deer (Odocoileus virginianus). B. microti survives well in refrigerated blood, making transfusion-transmitted babesiosis a real risk - it is one of the most commonly reported transfusion-transmitted diseases in the USA.
- Goldman-Cecil Medicine, p. 3445-3450; Rosen's Emergency Medicine, p. 2702
Epidemiology
-
~2,000 cases/year reported in the USA (largely underreported); became nationally reportable in 2011.
-
95% of US cases come from 7 states: Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin.
-
Seasonal peak: May to August (nymphal tick-feeding period); average patient age 62, two-thirds male.
-
Co-infection with Lyme disease is common (same tick vector, same reservoirs) - up to 50% of babesiosis cases in some series.
-
250 transfusion-acquired cases of B. microti reported; transplacental transmission documented.
-
Rosen's Emergency Medicine, p. 2701; Goldman-Cecil Medicine, p. 3445
Pathophysiology
-
The nymphal Ixodes tick (only 1-2 mm, easily overlooked) transmits the parasite during feeding; >50% of patients cannot recall a tick bite.
-
Sporozoites enter RBCs and undergo asexual reproduction (merozoites), causing hemolysis.
-
Pro-inflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-6, E-selectin, VCAM-1, ICAM-1) drive fever, sweats, chills, and headache.
-
Severe disease involves vascular stasis contributing to end-organ dysfunction.
-
Parasitemia ranges from <1% in mild cases to 70-85% in asplenic/immunocompromised patients.
-
Goldman-Cecil Medicine, p. 3450
Clinical Features
Incubation period: 1-4 weeks after tick exposure (up to 9 weeks after blood transfusion).
Mild to moderate (most common):
- Gradual onset of flu-like illness: malaise, fatigue, fever (up to 40°C), chills, sweats, myalgias, headache, anorexia
- Nausea, vomiting, emotional lability, hyperesthesias, dark urine
- No rash (differentiates from Lyme disease)
- Splenomegaly and hepatomegaly on exam
- ~25% of adult B. microti infections are subclinical; 50% in children
Lab findings:
- Hemolytic anemia (most patients)
- Thrombocytopenia
- Normal or low WBC (leukopenia)
- Elevated LDH, bilirubin (indirect), aminotransferases
- Hemoglobinuria in severe cases
Severe disease (asplenic, elderly >50 yrs, immunocompromised, HIV, transplant, malignancy):
-
Hypotension, high persistent non-periodic fever (40-41°C)
-
Severe hemolytic anemia, hemoglobinuria, jaundice
-
Acute renal failure
-
Non-cardiogenic pulmonary edema / ARDS (up to 20% of severe cases)
-
DIC, heart failure, hepatic necrosis
-
Multiorgan failure and coma in fatal cases
-
B. divergens in Europe: nearly all in splenectomized patients, ~one-third fatality rate
-
Mortality in hospitalized patients: 6-9%; up to 21% in immunocompromised
-
Goldman-Cecil Medicine, p. 3450; Rosen's Emergency Medicine, p. 2702; Murray & Nadel Respiratory Medicine, p. 1354
Diagnosis
1. Blood Smear (Giemsa-stained, thick and thin)
- Intraerythrocytic ring forms resembling P. falciparum early trophozoites
- Key distinguishing features from malaria:
- No hemozoin (malarial pigment)
- No schizonts or gametocytes
- Parasites can be extracellular (extraerythrocytic merozoites free in plasma)
- Multiple parasites per RBC common
- Tetrad/"Maltese cross" form - pathognomonic but rare in B. microti, more common with B. duncani
Fig. 8.53 from Robbins Pathology - Erythrocytes infected with Babesia, showing ring forms and the classic Maltese cross tetrad:
Robbins, Cotran & Kumar Pathologic Basis of Disease, Fig. 8.53 - Note the characteristic Maltese cross (tetrad) forms within RBCs alongside ring forms.
Fig. 324-1 from Goldman-Cecil Medicine - B. microti blood smear showing ring forms and extraerythrocytic parasite clusters (arrows):
Goldman-Cecil Medicine, Fig. 32-1 - B. microti human infection (Nantucket Island). Predominance of ring forms with cluster of extraerythrocytic parasites (arrows) free in plasma.
2. PCR
- Most sensitive, especially in early infection before antibody response
- Useful for blood donor screening
3. Serology (Indirect Immunofluorescence / IFA)
- IFA titer typically rises to ≥1:1024 within first few weeks
- IgM-IFA sensitive and specific in acute disease
- ELISA and IFA sensitivity rises significantly after 5 days of illness
- High seroprevalence in endemic areas limits usefulness for population screening
- Not useful for B. divergens (fulminant course, too rapid)
4. Animal inoculation
-
Blood injected into hamster/gerbil; parasitemia at 1-4 weeks confirms diagnosis (rarely used clinically)
-
Rosen's Emergency Medicine, p. 2702; Murray & Nadel Respiratory Medicine, p. 1354
Treatment
Mild to Moderate Disease (Immunocompetent, Ambulatory)
| Regimen | Dosing |
|---|
| Preferred: Atovaquone + Azithromycin | Atovaquone 750 mg PO q12h (with fatty meal) + Azithromycin 500 mg PO day 1, then 250 mg/day for 7-10 days |
| Alternative: Clindamycin + Quinine | Clindamycin 600 mg PO q8h + Quinine 650 mg PO q8h for 7-10 days (more side effects) |
Severe Disease (Hospitalized)
| Regimen | Dosing |
|---|
| Preferred: Atovaquone + Azithromycin | Atovaquone 750 mg PO q12h + Azithromycin 500 mg IV q24h until improvement, then oral step-down |
| Alternative: Clindamycin + Quinine | Clindamycin 600 mg IV q6h + Quinine 650 mg PO q8h until improvement, then oral step-down |
Highly Immunocompromised
- Treat for at least 6 consecutive weeks, including 2 final weeks with no detectable parasitemia on smear
- Azithromycin dose should be 500-1000 mg/day
- Relapsing disease: consider experimental regimens (doxycycline, proguanil, pentamidine, or TMP-SMX) under expert guidance
Exchange Transfusion
- Indicated for severe cases with high parasitemia (>10%), severe hemolysis, or organ compromise
- Rapidly reduces parasite load
Non-splenectomized immunocompetent patients
-
Many recover without specific therapy, but prolonged fatigue is common; treatment is still recommended
-
Goldman-Cecil Medicine, p. 3451 (Table 324-1); Rosen's Emergency Medicine, p. 2702; Murray & Nadel Respiratory Medicine, p. 1354
Key Distinguishing Points: Babesiosis vs. Malaria
| Feature | Babesiosis | Malaria |
|---|
| Hemozoin pigment | Absent | Present |
| Schizonts | Absent | Present |
| Gametocytes | Absent | Present |
| Maltese cross/tetrad | Present (rare) | Absent |
| Extracellular parasites | Common | Absent |
| RBC enlargement | Absent | Present with P. vivax/ovale |
| Periodicity of fever | Non-periodic | Periodic (tertian/quartan) |
Prevention
- Tick avoidance (protective clothing, permethrin-treated gear, DEET repellent)
- Tick checks after outdoor exposure in endemic areas
- Blood donor screening with B. microti-specific tests in endemic regions (now implemented in the USA)
- Asplenic/immunocompromised patients should be counseled about tick exposure risk
Sources:
- Goldman-Cecil Medicine (International Ed.), pp. 3445-3455
- Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 373-374
- Rosen's Emergency Medicine, pp. 2701-2702
- Murray & Nadel's Textbook of Respiratory Medicine, p. 1354